Quantifying the Value of Introducing an Oral Drug Delivery Option for Edaravone: A Review of Analyses Evaluating the Economic Impact of Oral versus Intravenous Formulations
Open Access
- 26 July 2022
- journal article
- review article
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. 14, 499-511
Abstract
Background: Drug formulation and route of administration can have an impact on not only patients' quality of life and disease outcomes but also costs of care. It is essential for decision makers to use appropriate economic modeling methods to guide drug coverage policies and to support patients' decision-making. Purpose: To illustrate key cost considerations for decision makers in economic evaluation of innovative oral formulations as alternatives to intravenous medication. Materials and Methods: A structured literature review was conducted using the PubMed database to examine methods used for quantifying the economic impact of introducing a new oral pharmaceutical formulation as an alternative to intravenous medication. To illustrate the methods described in this review, a cost-minimization analysis was conducted to quantify the impact of introducing an oral formulation of a medication originally developed as an intravenous treatment for amyotrophic lateral sclerosis. Results: We identified 14 published evaluations of oral and intravenous formulations from 10 countries across a variety of disease areas. The identified studies used cost-effectiveness (n=10), cost-minimization (n=2), and cost-calculation (n=2) modeling approaches. All but one (13/14) reported outcomes from payers' perspective, while societal perspectives were also incorporated in 3 of the reviewed evaluations. One study estimated costs from a public hospital's perspective. Only a subset of the identified studies accounted for the effects of safety (n=6) or efficacy (n=8) differences on treatment costs when estimating the costs of a formulation choice. Many studies that omitted these aspects did not include rationales for their decisions. Conclusion: We found significant design variations in published models that estimated the impact of an additional formulation option on the treatment costs to payers and the society. Models need to be accompanied with clear descriptions on rationales for their time horizons and assumptions on how different formulations may affect healthcare costs from the selected perspectives.Keywords
This publication has 24 references indexed in Scilit:
- Amyotrophic Lateral Sclerosis: ReviewSeminars in Neurology, 2015
- Oral Chemotherapy and Patient Perspective in Solid Tumors: A National Survey by the Italian Association of Medical OncologyTumori Journal, 2015
- Caregiver burden in amyotrophic lateral sclerosis is more dependent on patients’ behavioral changes than physical disability: a comparative studyBMC Neurology, 2012
- How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies.2012
- Mortality, health, social and economic consequences of amyotrophic lateral sclerosis: a controlled national studyJournal of Neurology, 2012
- Cost Comparison of Linezolid Versus Vancomycin for Treatment of Complicated Skin and Skin‐Structure Infection Caused by Methicillin‐Resistant Staphylococcus aureus in QuebecCanadian Journal of Infectious Diseases and Medical Microbiology, 2012
- Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review)Neurology, 2009
- Cost-Effectiveness Analysis of Capecitabine Compared with Bolus 5-Fluorouracil/l-Leucovorin for the Adjuvant Treatment of Colon Cancer in JapanPharmacoEconomics, 2009
- Economic Evaluation of Treatment Administration Strategies of Ganciclovir for Cytomegalovirus Retinitis in HIV/AIDS Patients in ThailandPharmacoEconomics, 2007
- The Cost-Effectiveness and Budget Impact of Intravenous Versus Oral Proton Pump Inhibitors in Peptic Ulcer HemorrhageClinical Gastroenterology and Hepatology, 2006